Exploring biomarkers for personalized treatment in esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational biomarker study aims to analyze circulating tumor cells (CTCs) and other blood-based biomarkers in approximately 100 patients with resectable adenocarcinomas of the esophagus and gastro-esophageal junction. Blood samples will be collected from both peripheral and tumor-draining veins to assess the prognostic value of these biomarkers. The study seeks to improve preoperative staging and identify patients at risk for metastasis, potentially leading to better treatment stratification. Data collected will inform future studies on the predictive role of these biomarkers in surgical management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* histologically proven adenocarcinoma of the GEJ type I and II, resectable, non-metastatic tumor
* age ≥18
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2,
* American Society of Anesthesiologists (ASA) \< 4.
* pre-treatment stage cT1N+ M0 or cT2-4a N0/N+, M0 GEJ type I and II adenocarcinomas can be included. In case of stage cT4a, curative resectability has to be explicitly verified by the local surgical investigator prior inclusion.
* Written informed consent and the ability to understand the nature of the study and the study-related procedures and to comply with them has to be ensured.

Exclusion Criteria:

* tumors of squamous, adenosquamous or other non-adenocarcinoma histology
* patients with inoperable or metastatic GEJ type I and II adenocarcinoma, GEJ type I and II adenocarcinoma staged cT1N0 and cT4b, GEJ type I and II cT4a evaluated as not curatively resectable by the local surgical investigator
* unsigned informed consent

Where it's running

• University Hospital Cologne
  Cologne, North Rhine-Westphalia, Germany Recruiting
• Universitätsklinikum Münster
  Münster, North-Rhine Westfalia, Germany Not yet recruiting

Study contacts

• Principal investigator: Nikolas Stoecklein, MD — Surgery, University Hospital Düsseldorf Germany
• Study coordinator: Nikolas H Stoecklein, MD
• Email: Nikolas.Stoecklein@med.uni-duesseldorf.de
• Phone: 004921181

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Active surveillance for oesophageal cancer after chemoradiotherapy

  This study is testing whether closely monitoring patients with locally advanced oesophageal cancer after they finish chemoradiotherapy can be a safe and effective alternative to immediate surgery.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT04886635

• AI-based precision oncology clinical trial matching and registry

  This study is testing whether an AI tool can help match cancer patients with the right clinical trials based on their specific cancer details to see if it improves their chances of getting into trials and their overall outcomes.

  Recruiting at 68 sites Massive Bio, Inc. · Birmingham, Alabama and 67 other locations · NCT03452774

• Survey for patients with esophageal cancer and upper digestive diseases

  This study is trying to gather information from patients with esophageal cancer and other upper digestive issues to see how they are doing after treatment and improve future care.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT02530983

• Personalized Ultrafractionated Stereotactic Radiotherapy with Perioperative FLOT for GEJ and Esophageal Cancer

  This trial tests adding a personalized, ultra-fractionated radiotherapy boost (PULSAR) to standard perioperative FLOT chemotherapy for patients with esophageal or gastroesophageal junction cancer to see if it can be used safely.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07700420

• Preventing nausea and vomiting during multi-cycle chemo and immunotherapy in esophageal and lung cancer

  This study tests a combination antiemetic with dexamethasone to see if it lowers nausea and vomiting in adults with esophageal or lung cancer receiving several cycles of chemo plus immunotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07617246

• Ivonescimab plus FOLFOX for advanced HER2-negative stomach and gastroesophageal junction adenocarcinoma

  This study tests whether adding ivonescimab to standard FOLFOX chemotherapy helps people with advanced, HER2-negative stomach or gastroesophageal junction adenocarcinoma as first-line treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Santa Monica, California and 1 other locations · NCT07070466

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.